Is MAZE or MBRX more undervalued in 2026?

CirclFi compares Maze Therapeutics, Inc. (MAZE) and Moleculin Biotech, Inc. (MBRX) using 13 institutional-grade valuation models. MAZE has a Quality of Company score of 5.4/10 while MBRX scores 4.3/10.

Which is a better buy — MAZE or MBRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MAZE and MBRX valuations compare?

MAZE at $26.40 and MBRX at $2.74 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MAZE vs MBRX Valuation Comparison 2026 — Intrinsic Value Analysis

MAZE

Biotechnology

Maze Therapeutics, Inc.

Quality

5.4

out of 10

Value Trap

—

Price

$26.40

Last close

Models

9/13

Active

MBRX

Biotechnology

Moleculin Biotech, Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$2.74

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	MAZE Fair Value	MAZE Upside	MBRX Fair Value	MBRX Upside
Bayesian DCF	Intrinsic	$3.40	-87.1%	$1.77	-35.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.53	-98.0%	$7.87	+187.3%
Dynamic NAV	Asset-Based	$7.76	-71.4%	$6.78	+147.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MAZE vs MBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MAZE vs MBRX — Which Stock Is More Undervalued?

MAZE scores higher with a 5.4/10 quality rating vs MBRX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Maze Therapeutics, Inc. (MAZE) and Moleculin Biotech, Inc. (MBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MAZE currently trades at $26.40 with a QOC of 5.4/10, while MBRX trades at $2.74 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).